Wall Street brokerages expect that Genomic Health, Inc. (NASDAQ:GHDX) will post $0.09 earnings per share for the current fiscal quarter, according to Zacks. Seven analysts have provided estimates for Genomic Health’s earnings. The highest EPS estimate is $0.13 and the lowest is $0.07. Genomic Health posted earnings of $0.04 per share during the same quarter last year, which indicates a positive year over year growth rate of 125%. The business is scheduled to report its next quarterly earnings report on Tuesday, February 13th.

According to Zacks, analysts expect that Genomic Health will report full-year earnings of ($0.08) per share for the current fiscal year, with EPS estimates ranging from ($0.15) to ($0.04). For the next financial year, analysts expect that the firm will post earnings of $0.34 per share, with EPS estimates ranging from $0.25 to $0.52. Zacks’ earnings per share calculations are a mean average based on a survey of analysts that that provide coverage for Genomic Health.

Genomic Health (NASDAQ:GHDX) last posted its quarterly earnings data on Wednesday, November 8th. The medical research company reported $0.03 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.01) by $0.04. Genomic Health had a negative return on equity of 1.79% and a negative net margin of 1.30%.

A number of research firms recently weighed in on GHDX. Canaccord Genuity restated a “buy” rating and issued a $42.00 price objective on shares of Genomic Health in a report on Tuesday. Zacks Investment Research downgraded Genomic Health from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Barclays reiterated a “sell” rating and set a $28.00 price target on shares of Genomic Health in a report on Monday, January 8th. William Blair downgraded Genomic Health from an “outperform” rating to a “market perform” rating in a report on Wednesday, December 20th. Finally, BidaskClub upgraded Genomic Health from a “sell” rating to a “hold” rating in a report on Tuesday, December 19th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $32.14.

Shares of Genomic Health (NASDAQ GHDX) opened at $34.61 on Wednesday. The firm has a market capitalization of $1,231.40, a price-to-earnings ratio of -288.42 and a beta of 0.66. Genomic Health has a 1-year low of $26.37 and a 1-year high of $37.50.

In other news, insider Laura Leber sold 21,000 shares of the stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $33.29, for a total transaction of $699,090.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, COO G Bradley Cole sold 5,000 shares of the stock in a transaction dated Tuesday, November 7th. The stock was sold at an average price of $31.47, for a total transaction of $157,350.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 65,717 shares of company stock valued at $2,158,232. Company insiders own 46.20% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. Aurora Investment Counsel bought a new position in shares of Genomic Health during the 4th quarter worth about $1,879,000. Public Employees Retirement System of Ohio bought a new position in shares of Genomic Health during the 3rd quarter worth about $444,000. GSA Capital Partners LLP boosted its position in shares of Genomic Health by 43.7% during the 3rd quarter. GSA Capital Partners LLP now owns 63,100 shares of the medical research company’s stock worth $2,025,000 after purchasing an additional 19,200 shares in the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of Genomic Health during the 3rd quarter worth about $138,000. Finally, Point72 Asset Management L.P. bought a new position in shares of Genomic Health during the 3rd quarter worth about $350,000. 89.83% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Genomic Health, Inc. (GHDX) Expected to Announce Earnings of $0.09 Per Share” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was copied illegally and republished in violation of international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/17/genomic-health-inc-ghdx-expected-to-announce-earnings-of-0-09-per-share.html.

Genomic Health Company Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Get a free copy of the Zacks research report on Genomic Health (GHDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.